AP717A - Process for preparing sildenafil. - Google Patents

Process for preparing sildenafil. Download PDF

Info

Publication number
AP717A
AP717A APAP/P/1997/001009A AP9701009A AP717A AP 717 A AP717 A AP 717A AP 9701009 A AP9701009 A AP 9701009A AP 717 A AP717 A AP 717A
Authority
AP
ARIPO
Prior art keywords
group
solvent
sodium
tertiary
amine
Prior art date
Application number
APAP/P/1997/001009A
Other languages
English (en)
Other versions
AP9701009A0 (en
Inventor
Peter James Dunn
Albert Shaw Wood
Original Assignee
Pfizer Ireland Pharmaceuticals
Pfizer Res & Development Company N V /S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP717(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals, Pfizer Res & Development Company N V /S A filed Critical Pfizer Ireland Pharmaceuticals
Publication of AP9701009A0 publication Critical patent/AP9701009A0/xx
Application granted granted Critical
Publication of AP717A publication Critical patent/AP717A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
APAP/P/1997/001009A 1996-06-14 1997-06-02 Process for preparing sildenafil. AP717A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (2)

Publication Number Publication Date
AP9701009A0 AP9701009A0 (en) 1997-07-31
AP717A true AP717A (en) 1999-01-04

Family

ID=10795332

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001009A AP717A (en) 1996-06-14 1997-06-02 Process for preparing sildenafil.

Country Status (48)

Country Link
US (2) US5955611A (ja)
EP (2) EP0812845B1 (ja)
JP (2) JP2866841B2 (ja)
KR (1) KR100207352B1 (ja)
CN (2) CN1106399C (ja)
AP (1) AP717A (ja)
AR (1) AR003401A1 (ja)
AT (2) ATE182150T1 (ja)
AU (1) AU697684B2 (ja)
BG (1) BG62554B1 (ja)
BR (1) BR9703580A (ja)
CA (1) CA2207694C (ja)
CO (1) CO4780028A1 (ja)
CZ (1) CZ290942B6 (ja)
DE (2) DE69723846T2 (ja)
DK (2) DK0916675T3 (ja)
DZ (1) DZ2247A1 (ja)
EA (1) EA000102B1 (ja)
EG (1) EG24123A (ja)
ES (2) ES2201397T3 (ja)
GB (1) GB9612514D0 (ja)
GR (1) GR3031087T3 (ja)
HK (1) HK1033459A1 (ja)
HN (1) HN1997000072A (ja)
HR (1) HRP970326B1 (ja)
HU (1) HU224497B1 (ja)
ID (1) ID18745A (ja)
IL (3) IL125411A (ja)
IN (5) IN187350B (ja)
IS (2) IS1922B (ja)
MA (1) MA24205A1 (ja)
MX (1) MX9704433A (ja)
NO (2) NO304551B1 (ja)
NZ (1) NZ328084A (ja)
OA (1) OA10426A (ja)
PE (2) PE1299A1 (ja)
PL (1) PL189333B1 (ja)
PT (1) PT916675E (ja)
RS (2) RS49653B (ja)
SA (1) SA97180124B1 (ja)
SG (1) SG50024A1 (ja)
SI (2) SI0916675T1 (ja)
SK (5) SK283894B6 (ja)
TN (1) TNSN97102A1 (ja)
TR (1) TR199700470A2 (ja)
UA (1) UA27085C2 (ja)
UY (2) UY24585A1 (ja)
ZA (1) ZA975259B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
EP0977756A1 (en) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
BR9809508A (pt) * 1997-05-29 2000-06-20 Mochida Pharm Co Ltd Agente terapêutico para disfunção de ereção
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE59803108D1 (de) 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
PL343794A1 (en) 1998-04-20 2001-09-10 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
AU1888800A (en) * 1999-09-13 2001-04-17 Cipla Limited A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CN1378547A (zh) 1999-10-11 2002-11-06 辉瑞大药厂 用作磷酸二酯酶抑制剂的5－(2－取代的－5－杂环基磺酰基吡啶－3－基)－二氢吡唑并[4,3－d]嘧啶－7－酮类化合物
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
HUP0301207A3 (en) * 2000-06-22 2006-02-28 Pfizer Novel process for the preparation of pyrazolopyrimidinones
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
YU51701A (sh) * 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
MXPA04001891A (es) * 2001-08-28 2004-06-15 Schering Corp Inhibidores policiclicos de guanina fosfodiesterasa v.
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
JP2007517803A (ja) 2004-01-05 2007-07-05 テバ ファーマシューティカル インダストリーズ リミティド シルデナフィル塩基とクエン酸塩の製造方法
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CN101563348B (zh) 2006-12-21 2011-08-24 上海特化医药科技有限公司 西地那非的制备方法及其中间体
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
WO2010067140A1 (es) 2008-12-12 2010-06-17 Siegfried Rhein S.A. De C.V. Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
EP0526004A1 (en) * 1991-07-09 1993-02-03 Pfizer Limited Pyrazolopyrimidinone antianginal agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
EP0977756A1 (en) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
EP0526004A1 (en) * 1991-07-09 1993-02-03 Pfizer Limited Pyrazolopyrimidinone antianginal agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem. Vol. 30, No. 1, 1987 pp. 91-96 XP 002040681, HAMILTON et al.: "Synthesis and Structure-Activity Relationships of Pyrazolo[4,3-d pyrimidin-7-ones as Adenosine Receptor Antagonists" Conversion of "6" to "5". *

Also Published As

Publication number Publication date
UY24612A1 (es) 2000-09-29
IL125411A (en) 2000-02-29
SK283894B6 (sk) 2004-04-06
UY24585A1 (es) 1997-12-02
UA27085C2 (uk) 2000-02-28
SA97180124A (ar) 2005-12-03
PE20011303A1 (es) 2001-12-25
PE1299A1 (es) 1999-01-13
DK0812845T3 (da) 1999-11-29
RS49653B (sr) 2007-09-21
TR199700470A2 (xx) 1998-01-21
HK1033459A1 (en) 2001-08-31
ES2201397T3 (es) 2004-03-16
GB9612514D0 (en) 1996-08-14
JPH1081688A (ja) 1998-03-31
CN1106399C (zh) 2003-04-23
CZ290942B6 (cs) 2002-11-13
HN1997000072A (es) 1997-12-26
BR9703580A (pt) 1998-11-10
NO985064L (no) 1997-12-15
ID18745A (id) 1998-05-07
IL121000A (en) 2000-02-29
EP0916675B1 (en) 2003-07-30
OA10426A (en) 2001-12-07
IL125411A0 (en) 1999-03-12
EA000102B1 (ru) 1998-08-27
EP0812845B1 (en) 1999-07-14
HUP9701048A3 (en) 2000-10-30
BG101569A (en) 1998-01-30
IN187320B (ja) 2002-03-23
DE69723846D1 (de) 2003-09-04
PT916675E (pt) 2003-11-28
TNSN97102A1 (fr) 2005-03-15
IN187317B (ja) 2002-03-23
YU25497A (sh) 1998-12-23
IN187318B (ja) 2002-03-23
CA2207694A1 (en) 1997-12-14
ATE182150T1 (de) 1999-07-15
ATE246194T1 (de) 2003-08-15
DE69700321T2 (de) 1999-11-04
BG62554B1 (bg) 2000-02-29
AP9701009A0 (en) 1997-07-31
SK283897B6 (sk) 2004-04-06
US5955611A (en) 1999-09-21
ES2134051T3 (es) 1999-09-16
HU9701048D0 (en) 1997-08-28
HRP970326B1 (en) 2000-10-31
EP0812845A1 (en) 1997-12-17
CO4780028A1 (es) 1999-05-26
EP0916675A3 (en) 1999-07-14
AU697684B2 (en) 1998-10-15
SI0916675T1 (en) 2003-12-31
CZ181197A3 (cs) 1998-03-18
CN1149206C (zh) 2004-05-12
JP2866841B2 (ja) 1999-03-08
SK283896B6 (sk) 2004-04-06
MX9704433A (es) 1998-11-30
EP0916675A2 (en) 1999-05-19
EA199700061A1 (ru) 1997-12-30
DZ2247A1 (fr) 2002-12-18
AR003401A1 (es) 1998-08-05
MA24205A1 (fr) 1997-12-31
NO304551B1 (no) 1999-01-11
NO985064D0 (no) 1998-10-30
HU224497B1 (hu) 2005-10-28
IS1922B (is) 2004-03-15
SK283895B6 (sk) 2004-04-06
SG50024A1 (en) 1998-06-15
HUP9701048A2 (hu) 1998-12-28
DE69723846T2 (de) 2004-03-04
AU2487897A (en) 1997-12-18
RS49924B (sr) 2008-09-29
JPH11171879A (ja) 1999-06-29
CN1168376A (zh) 1997-12-24
GR3031087T3 (en) 1999-12-31
DE69700321D1 (de) 1999-08-19
DK0916675T3 (da) 2003-10-27
US6066735A (en) 2000-05-23
IN187350B (ja) 2002-03-30
NZ328084A (en) 1998-08-26
HRP970326A2 (en) 1998-06-30
IN187319B (ja) 2002-03-23
RS20060484A (en) 2007-04-10
KR100207352B1 (en) 1999-07-15
CN1282740A (zh) 2001-02-07
KR980002051A (ko) 1998-03-30
SK283893B6 (sk) 2004-04-06
EG24123A (en) 2008-07-06
IS6634A (is) 2002-11-25
SK74397A3 (en) 1998-06-03
IS1923B (is) 2004-03-15
IL121000A0 (en) 1997-11-20
SI0812845T1 (en) 1999-12-31
CA2207694C (en) 1999-11-23
ZA975259B (en) 1997-12-15
IS4503A (is) 1997-12-15
NO306115B1 (no) 1999-09-20
PL189333B1 (pl) 2005-07-29
PL320555A1 (en) 1997-12-22
JP3058863B2 (ja) 2000-07-04
SA97180124B1 (ar) 2006-02-08
NO972481D0 (no) 1997-05-30
NO972481L (no) 1997-12-15

Similar Documents

Publication Publication Date Title
AP717A (en) Process for preparing sildenafil.
EP0274379B1 (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
US6207829B1 (en) Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
EP1092720B1 (en) Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof
US20010012900A1 (en) 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one a process for the preparation thereof and the use thereof
US6180787B1 (en) Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides
US4292431A (en) Process for the production of hydroxymethylimidazoles
JP2008094744A (ja) ビスアミノールエーテル化合物を用いるピペリジン−４−オン誘導体の製造方法
EP0588372B1 (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
KR100364226B1 (ko) 7-할로-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1.8]나프티리딘-3-카복실레이트의 제조방법
JP5088893B2 (ja) ピペリジン−４−オン誘導体の製造方法